Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for hormone‑sensitive metastatic prostate cancer:
- Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (2025) NICE technology appraisal guidance 1109
- Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (2023) NICE technology appraisal guidance 903
- Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (2021) NICE technology appraisal guidance 741
- Enzalutamide for treating hormone-sensitive metastatic prostate cancer (2021) NICE technology appraisal guidance 712
This page was last updated: